NASH in HIV.

Journal Article (Journal Article;Review)

PURPOSE OF REVIEW: Aging-related comorbidities, including liver disease, represent the main drivers of morbidity and mortality in people with HIV (PWH). Nonalcoholic fatty liver disease (NAFLD) seems a frequent comorbidity in aging PWH nowadays. NAFLD results from a fat deposition into the liver parenchyma that may evolve to nonalcoholic steatohepatitis (NASH), a state of hepatocellular inflammation and injury in response to the accumulated fat leading to liver fibrosis and cirrhosis. We here review the current status of knowledge regarding this emerging comorbidity in PWH. RECENT FINDINGS: Recent studies suggest that PWH are at higher risk for both NASH and NASH-related liver fibrosis. Several hypothesized pathogenic mechanisms may account for this finding, including increased metabolic comorbidities, hepatotoxic effect of lifelong antiretroviral therapy, and chronic HIV infection. In clinical practice, non-invasive diagnostic tests, such as serum biomarkers and elastography, may help identify patients with NASH-related fibrosis, thus improving risk stratification, and enhancing clinical management decisions, including early initiation of interventions such as lifestyle changes and potential pharmacologic interventions. Clinicians should remain informed of the frequency, significance, and diagnostic and management approach to NASH in PWH.

Full Text

Duke Authors

Cited Authors

  • Cervo, A; Shengir, M; Patel, K; Sebastiani, G

Published Date

  • December 2020

Published In

Volume / Issue

  • 17 / 6

Start / End Page

  • 601 - 614

PubMed ID

  • 32984925

Electronic International Standard Serial Number (EISSN)

  • 1548-3576

Digital Object Identifier (DOI)

  • 10.1007/s11904-020-00531-0

Language

  • eng

Conference Location

  • United States